Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19902554 | 0.95 | CHRNA7 (0.39) | CHRNA7SMN1; SMN2KAT2BATM | |
| SCHEMBL17452550 | 0.85 | CHRNA7 (0.32) | CHRNA7SMN1; SMN2KAT2B | |
| SCHEMBL17456224 | 0.79 | CHRNA7 (0.35) | CHRNA7SMN1; SMN2KAT2BKDM4E | |
| SCHEMBL19902533 | 0.75 | JAK1 (0.45) | CHRNA7KAT2BDRD2JAK2JAK1 | |
| SCHEMBL19902416 | 0.73 | ALDH1A1 (0.56) | KAT2BKDM4E | |
| SCHEMBL1785783 | 0.72 | CHRNA7 (0.41) | CHRNA7SMN1; SMN2KAT2BKDM4EATM | |
| SCHEMBL1791199 | 0.67 | CHRNA7 (0.44) | CHRNA7KAT2BKDM4EATMPARP1 | |
| SCHEMBL1789276 | 0.67 | ATM (0.48) | CHRNA7SMN1; SMN2KAT2BATMPARP1 | |
| SCHEMBL19902312 | 0.66 | PRMT5 (0.45) | KDM4EATMPOLBPARP1JAK2 | |
| SCHEMBL1786982 | 0.66 | ATM (0.50) | CHRNA7SMN1; SMN2KAT2BATMPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | CHRNA7 1851/4885SMN1; SMN2 1146/4885KAT2B 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.